In part two of our Truth on Diabetes series, you will understand diabetes treatments as we sit down with Dr. Arpeta Gupta to dissect the latest guidelines and the transformative impact of newer diabetes medications. We will discuss how SGLT2 inhibitors and GLP-1 agonists are not only enhancing glycemic control but also delivering critical cardiovascular and renal benefits. We revisit the troubled history of TZD drugs like Avandia and contrast it with the safety profiles of today's leading medications. Drs. Gupta and Koren dive into the complexities of managing diabetes care across multiple specialties and share actionable strategies to improve interdisciplinary communication for better patient outcomes.
Navigating the hurdles of diabetes treatment access is no small feat, and we tackle this issue head-on by examining how insurance policies and cost barriers affect patient care. From the implications of prior authorization and step therapy to the financial strain on patients, particularly those on federal plans, we leave no stone unturned. We also explore the exciting potential of federal drug price negotiations and recent strides in lowering insulin costs. The significance of selecting therapies that safeguard end organs and the advantages of participating in clinical trials for cutting-edge treatments are underscored, ensuring you leave with a comprehensive view of the future landscape of diabetes care.
Koren's Key Three Takeaways:
Recording Date: June 19, 2024
Be a part of advancing science by participating in clinical research.
Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.com
Listen on Spotify
Listen on Apple Podcasts
Watch on YouTube
Share with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.
Follow us on Social Media:
Facebook
Instagram
X (Formerly Twitter)
LinkedIn
Want to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.com
Music: Storyblocks - Corporate Inspired
Thank you for listening!
